Inhaled drug delivery

Medicines That Deliver.

Paint Therapeutics engineers peptide-drug conjugates to enhance the therapeutic performance of inhaled medicines.

Learn MoreSee Our Pipeline
Scroll to Learn More

01 · Our Mission

At Paint, we're redefining inhaled drug delivery: getting medicines to the lungs and keeping them there.

Too many pulmonary therapies fail for delivery reasons, not biology. We're closing that gap.

Learn More
Textured magenta and orange molecule surrounded by floating spheres

02 · Our Science

We paint medicines onto the tissues that need them

Paint Therapeutics' lead platform, PulmoPaint, is a peptide-drug conjugate (PDC) technology built to improve how pulmonary therapies perform once they reach the lung.

Paintbrush coating a glossy molecule above a teal liquid surface

Rather than developing a single molecule, PulmoPaint pairs peptide targeting and linker chemistry with different payloads to solve a recurring problem in pulmonary medicine: drugs that clear too fast, distribute too broadly, or lose potency before they can do their job.

Learn More About the Science

PulmoPaint conjugates are designed to

  • Extend lung residence time

    Keeping active drug where it’s needed for longer.

  • Control release kinetics

    Delivering the payload on a therapeutically useful timeline rather than in an immediate burst.

  • Tune potency through linker design

    Allowing the same platform to be adapted across different payloads and disease targets.

  • Minimize immunogenicity

    Supported by non-immunogenicity data in preclinical mouse models.

03 · Pipeline

A pulmonary-focused pipeline built on one platform.

Our lead program applies PulmoPaint to pulmonary arterial hypertension (PAH) — a rare, progressive, and life-threatening disease where current therapies leave meaningful room for improved performance, tolerability, and dosing convenience.

See Our Pipeline
Development pipeline03Programs
Pulmonary disease programs, development stages, and milestones
ProgramModalityIndicationPDC IDIND-enablingStatus
PT-Small moleculeSmall MoleculePulmonary arterial hypertension
Current development stage: PDC ID.
Candidate Nomination2027
PT-BiologicBiologicPulmonary arterial hypertension
Current development stage: PDC ID.
Lead Identification2027
UndisclosedMultipleLung diseases
Current development stage: PDC ID.
No status specified

PT-Small molecule

Modality
Small Molecule
Indication
Pulmonary arterial hypertension
Current development stage: PDC ID.
StatusCandidate Nomination2027

PT-Biologic

Modality
Biologic
Indication
Pulmonary arterial hypertension
Current development stage: PDC ID.
StatusLead Identification2027

Undisclosed

Modality
Multiple
Indication
Lung diseases
Current development stage: PDC ID.
StatusNo status specified